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Abstract
Glaucoma and cataract frequently coexist in our elderly population regardless of geo-
graphical location or ethnicity. Cataract extraction alone has demonstrated to reduce 
intraocular pressure in eyes either with or without glaucoma. However, this chapter 
focuses on how cataract surgery might be combined with different glaucoma surgical 
procedures, such as trabeculectomy, non-penetrating procedures and minimally invasive 
procedures (MIGS), as well as implantation of drainage devices like the Trabectome® 
and the iStent®, both used for trabecular flow increase; the CyPass® implant, which acts 
by increasing the uveoscleral flow; the XEN® implant that facilitates the drainage of the 
aqueous humor from the anterior chamber to the subconjunctival space and finally the 
endocyclophotocoagulation that decreases the aqueous humor production. Current sur-
gical options will be discussed, focusing on recently reported studies, analyzing the clini-
cal aspects that influence the choice for each surgical treatment.
Keywords: MIGS, glaucoma, cataract, IOP, combined surgery, novel glaucoma 
procedures
1. Introduction
Cataract and glaucoma are ranked as the leading causes of blindness worldwide (51 and 
8%, respectively). Cataract and glaucoma frequently coexist in our patient population. 
Phacoemulsification combined with trabeculectomy has historically been the preferred surgi-
cal approach for concurrently managing cataract and glaucoma. The severity of glaucoma 
must be taken into account for all cases of cataract surgery in glaucoma patients. In case of a 
refractory glaucoma; when more than three types of medication are required, with associated 
early stage cataract; it is advisable to postpone any phacoemulsification procedure until after 
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glaucoma surgery. However, all cases most be evaluated individually, and cataractogenous 
effect of the procedure should be considered in this situation. Moreover, cataract extraction 
performed after a filtering surgery may lead to a reduction of the bleb function.
2. When to combine surgeries and how to minimize complications
In the last few years, glaucoma surgery has undergone great advances when we are talking 
about surgical treatment of the glaucoma, one of the main points about this is combining 
cataract and glaucoma surgery [1].
We can combine cataract surgery with different glaucoma surgeries, such as trabeculectomy, 
implantation of drainage devices, non-penetrating procedures and minimally invasive proce-
dures (MIGS) to mention a few [1].
The success of them depends on several factors among which they can mention:
• Type of glaucoma
• Severity of damage
• Amount and time of use of topical medicine
• Previous surgery/s
• Type of surgery to be performed
Within this last group of surgeries are procedures and devices that seek to derive the aqueous 
humor toward the Schlemm’s channel, the suprachoroidal space, to the subconjunctival space 
and that reduce the aqueous humor production [1].
This opens a range of possibilities for the treatment of glaucoma, mainly in early stages of the 
disease, which turns it into a useful resource for the control of glaucoma and making it an 
option with fewer risks and complications than the classic procedures [1].
2.1. Newer surgical alternatives
Among the methods that can be used, FDA-approved, are Trabectome® and iStent® for 
use since 2006 and 2012, respectively, both used for trabecular flow increase, the recently 
approved CyPass® implant in 2016, acts by increasing the uveoscleral flow, the XEN® implant 
that facilitates the drainage of the aqueous humor from the anterior chamber to the subcon-
junctival space and finally the endocyclophotocoagulation that decreases the aqueous humor 
production [2].
It has now been established that the MIGS techniques are prepared for a decrease in intraocular 
pressure (IOP) at least 20% to be considered effective. In addition to being considered as safe, 
this means a very low incidence of adverse effects and complications, especially those that 
affect the patient’s vision.
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The efficacy and safety of some devices have been demonstrated by many multicenter 
studies [2].
The hypotensive effect of these techniques may be additional if combined with cataract sur-
gery, phacoemulsification specifically, with this combination is reporting the IOP description 
up to 40% [4]. The fact that those are techniques with a lower IOP decrease should not be seen 
as a problem and it is a mistake to compare these techniques with the standard surgery of 
glaucoma, trabeculectomy with mitomycin C, since they are not designed to replace the latter 
to fill the gap between medical treatment and more aggressive surgeries [3].
Any patient who undergo phacoemulsification of the lens gives us an opportunity to combine 
the surgery with a minimally invasive procedure of glaucoma. Due to the efficacy and safety 
profile, these procedures should be used in cases of mild-to-moderate glaucoma. Regarding 
the type of glaucoma, they are performed in open-angle primary and secondary to pseudoex-
foliation and pigment, except for endocyclophotocoagulation that can be used in other types 
of glaucoma. With all this, MIGS would help us gain time and delay, as far as possible, more 
aggressive surgery [3].
In situations in which we combine cataract surgery with some minimally invasive procedure, 
it is not easy to differentiate what proportion of the hypotensive effect is due to cataract sur-
gery and how much is due to the MIGS procedure. We can say that the hypotensive effect of 
cataract surgery alone reported by different authors is 2–4 mmHg in a variable period of time 
(1–7 years) [2, 3].
Some recommendations to facilitate the procedure or implantation of devices and to reduce 
the rate of intra and postoperative complications are: familiarization with the technique and/
or device to be implanted, use of the surgical microscope with different viewing angles, cor-
rect use of surgical goniolens and previous experience in procedures or surgeries involving 
surgical manipulation of the angle [2].
According to a meta-analysis, comparing the efficacy of iStent combined with cataract sur-
gery versus phacoemulsification alone in patients with glaucoma and cataract, the decrease in 
IOP was greater in the group in whom iStent was placed and this effect is even greater if more 
implantation is performed of a device [4].
2.2. Combined phacoemulsification and canaloplasty
Mention will be made of some of the minimally invasive procedures currently performed, 
beginning with canaloplasty. This procedure consists in the creation of two overlapping 
scleral flaps, the probing of the Schlemm’s canal with a catheter designed for that effect and 
the introduction of a suture with the aid of the same catheter and then knotted at its free ends 
to achieve a canal distension and a tension in the tissues of the trabecular meshwork with 
the consequent opening of the trabecular meshwork, ending with a watertight suture of the 
superficial flap. Better results are obtained when this procedure is combined with phacoemul-
sification of the lens. The reduction obtained is approximately 40% to 3 years with a success 
of up to 65–82% [5, 6].
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2.3. Combined phacoemulsification and iStent®
Another available procedure is the iStent implant, which consists of a metal device that is 
implanted at the level of the trabecular meshwork to create a bypass between the anterior 
chamber and the Schlemm’s canal. It is the smallest device that is implanted throughout the 
body as depicted in Figure 1. The method may be done in isolation or in combination with 
phacoemulsification of the lens; if implanted in conjunction with surgery of the lens, the 
moment in which it is implanted is variable, being able to be before or after the extraction of 
the lens, taking into account that it must be done with the pupil in miosis and under the direct 
visualization of the angle through a goniolens. The hypotensive effect of this device increases 
when it is associated with cataract surgery in the same surgical act, as well as with the number 
of implanted devices [4].
If we compare the IOP results, between cataract surgery and cataract surgery plus iStent 
implantation in PAOG patients with at least one medication and IOP ≥ 19 mmHg, at 15 months 
the IOP reduction was 17.3% and a 80% medication reduction in the iStent group, compared 
to 9% IOP reduction and 32% medication reduction (cataract surgery alone) [8].
Almost all of the randomized controlled trials show a mild IOP reduction (between 10 and 
20%). But when multiple iStents are implanted with cataract extraction, the IOP reduction is 
up to 40% with three stents, attention has turned toward using multiple iStents [7].
For multiple iStents alone (without cataract surgery), using the second-generation iStent 
inject among phakic and pseudophakic subjects, the results show a 29–48% IOP reduction 
from medicated baseline. At 1 year after implantation of two stents, 66% had IOP ≤18 mmHg 
off of medication, and the mean IOP reduction among all was 40% [8].
2.4. Combined phacoemulsification and CyPass®
One device used to increase drainage through the uveoscleral pathway is the CyPass Micro-
stent, which creates a communication between the suprachoroidal space and the anterior 
chamber. The CyPass Micro-stent is a fenestrated micro-stent made with a biocompatible 
Figure 1. iStent implant at the level of the trabecular meshwork to create a bypass between the anterior chamber and 
the Schlemm’s canal.
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polyamide, 6.35 mm in length and an external diameter of 510 μm. It is introduced under 
gonioscopic visualization at the level of the union of the scleral spur with the band of the 
ciliary body by a curved guide to follow the contour of the sclera along the supraciliar space. 
Trough physical and mechanical properties and a series of retaining rings at the proximal end 
of the device, the stability of the device is ensured in the supraciliar space. Different studies 
have shown that the implantation of this device decreases IOP both in isolation and in combi-
nation with cataract surgery, with an IOP decrease of approximately 30–35%, and this effect is 
maintained over time, as well as in the use of hypotensive medication from 1.4 drugs to 0.2 on 
average. The complications that can be observed after the implantation of this device are few 
and include loss of visual acuity, corneal edema, iris inflammation, cyclodialysis, hypotonia, 
migration or obstruction of the device and increase of IOP [9, 10].
CyPass with cataract extraction demonstrate a favorable safety profile. The mean IOP reduc-
tion was 5.5 mmHg (from 21.1 ± 5.91 to 15.6 ± 0.53 mmHg) which means a 37% decrease from 
baseline IOP and a 50% reduction in glaucoma medications [11].
This are the results at one-year follow-up from CyPass implantation alone in a recent 
multicenter interventional study. Baseline IOP was reduced from 24.5 ± 2.8 mmHg with 
2.2 ± 1.1 medications to 16.4 ± 5.5 mmHg with 1.4 ± 1.3 medications at 12 months. This was 
a 34.7% reduction in IOP. About 83% of eyes avoided conventional incisional glaucoma 
surgery [11].
2.5. Combined phacoemulsification and endocyclophotocoagulation
Cyclophotocoagulation, initially with a transscleral probe, typically used in refractory glau-
coma. Recent reports demonstrate the safety and efficacy of endocyclophotocoagulation 
(ECP) in the treatment of mild-to-moderate glaucoma. Similar to other MIGS, it is conjuncti-
val-sparing, blebless, and can be combined with cataract surgery. The laser endoscope probe 
can be inserted through a temporal 2.4 mm clear corneal wound into the anterior chamber 
and sulcus (filled with OVD). With direct visualization of the ciliary processes, the visible por-
tion of the ciliary process are treated with the diode laser (Iridex Oculight, Mountain View) at 
200 mW mean power and continuous duration. Approximately 270° of ciliary processes must 
be treated to the point of blanching and shrinking of the tissue. Overtreatment is defined by 
extreme blanching and a popping sound, which indicates an air-bubble explosion [12].
A 3-year outcomes of a prospective nonrandomized matched-control study comparing ECP 
with cataract extraction versus cataract extraction alone in medically controlled OAG, showed 
a 10.1% IOP reduction and a 73% medication reduction at 2 years in the treatment group. The 
control group (cataract surgery alone) showed a 0.8% IOP reduction and a 17% medication 
reduction at 2 years [12].
Another author reported retrospective results of endocyclophotocoagulation and cata-
ract extraction versus cataract extraction alone in mild-to-moderate glaucoma patients, the 
combined group had a 14.5% IOP reduction with 85% medication reduction at 36 months. 
The control group (phacoemulsification alone) 12.4% IOP reduction and a 13.3% medica-
tion reduction at 36 months. While there was no significant difference in the IOP reduction 
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between groups, there was a significant difference in medication reduction. At 36 months, the 
61.4% of the combined group versus 23.3% of the control group achieved an outcome of 20% 
IOP reduction with a decrease of at least one ocular hypotensive medication [13].
2.6 Combined phacoemulsification and Ex-PRESS®
The Ex-PRESS Glaucoma Filtration Device (Alcon Laboratories Inc., Fort Worth, TX) is a bio-
compatible [14], non-valved stainless steel device, designed to offer a fast an simple glau-
coma filtering device [15] and to provide a lower complication rate with a more stable early 
postoperative course [16]. Initially it was implanted through full-thickness sclera, directly 
under the conjunctiva, allowing aqueous drainage into the subconjunctival space [17], alone 
or in a combined procedure including phacoemulsification, as depicted in Figure 2. This tech-
nique however, was associated with a higher rate of complications: persistent hypotony, flat 
anterior chamber, choroidal detachment, suprachoroidal hemorrhage, conjunctival scarring 
and implant extrusion [18–21]. In 2005, Dahan and Carmichael [15] described an alternative 
device to be implanted under a scleral flap; these modifications provided satisfactory IOP 
control and reduced postoperative complications rates.
In a retrospective study by Lan et al. [22] that described the long-term outcomes of the Ex-Press 
Device combined with phacoemulsification in patients with primary open-angle glaucoma 
(POAG) and primary angle-closure glaucoma (PACG) and founded a lower postoperative 
IOP on the POAG group, in addition to more hypotony when compared to the PACG group. 
Three years after surgery the cumulative complete and qualified success rates were 63.3 and 
83.3% (POAG) and 53.3 and 73.3% (POAG), respectively.
Huerva et al. [23] evaluated the efficacy and safety of the Ex-Press device in combination with 
cataract surgery. After 1-year follow-up, 59.5% of patients had IOP control without medi-
cations and 10.8% with one medication. Complications in the early period included ocular 
hypotony and uveal effusion in 5%, as well as one case of re-intervention after 1-year due to 
uncontrolled IOP.
Figure 2. The Ex-PRESS Glaucoma Filtration Device implanted through full-thickness sclera in to the anterior chamber.
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3. Impact of cataract surgery on intraocular pressure
The leading cause of age-related, reversible blindness is cataract and the leading cause of 
irreversible blindness worldwide is glaucoma, the incidence of both cataract and elevated 
intraocular pressure, with or without glaucoma, increases with age [24]. There have been 
various reports of the effect of cataract surgery on intraocular pressure (IOP) in glaucoma-
tous and non-glaucomatous eyes, however, the magnitude and clinical significance of these 
changes continues to be debated. Some studies found a significant IOP reduction whereas 
others reported no significant change [25], depending on the type of glaucoma.
Intraocular pressure is the only known modifiable risk factor for the development and pro-
gression of glaucoma and intraocular pressure-lowering therapy delays its progression [26]. 
In glaucoma patients, the indication of cataract surgery differs from other patients, depending 
on various factors such as disease stage, preoperative IOP, number of medications, gonioscopy 
appearance, age and the experience and skills of the surgeon. Therefore every surgeon should 
recognize the influence of cataract surgery on IOP control in each type of glaucoma [27].
Previous reports of the effect of cataract surgery in IOP have reflected great variability in IOP 
reduction, related to angle anatomy, preoperative IOP and anterior chamber depth [28–30]. 
Identify which patient would experience an IOP-lowering response with cataract surgery 
alone could modify surgical decision-making.
3.1. Cataract surgery and open-angle glaucoma
In glaucomatous and normal eyes, cataract surgery produces a reduction in IOP, although 
these effects are more pronounced in patients with primary angle-closure glaucoma (PACG), 
there has been noticed a reduction in IOP also in POAG.
In a prospective study, Elgin et al. [31] compared the effect of cataract surgery on anterior 
segment parameters measured by optical biometry in patients with primary open-angle 
glaucoma (POAG) and pseudoexfoliation glaucoma (PSX), IOP decreased postoperatively 
1.9 mmHg and 3.1 mmHg in each group, they also observed a significant increase in anterior 
chamber depth in both groups with a greater increase in PSX patients probably related to cili-
ary zonular laxity.
In a retrospective study of the Swedish National Cataract Register Data, Charlotta Zetterström 
et al. [24] found that after cataract surgery, patients with glaucoma had a larger reduction in 
IOP than the group of patients who did not have glaucoma and patients with glaucoma and 
PSX had significantly greater IOP reduction than patients without these diagnoses. They also 
found that when high IOP was given as an indication for surgery, the IOP reduction after 
cataract surgery was greater.
Shingleton et al. [32] retrospectively evaluated the change in IOP and glaucoma medica-
tions after cataract surgery in glaucoma patients, glaucoma suspects and normal patients. At 
3 years follow-up IOP decreased 1.4 mmHg in glaucoma patients and glaucoma suspects and 
1.7 mmHg in normal patients, the number of glaucoma medications in the glaucoma group 
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did not show any significant change at follow-up and they found that after 3 years, 85% of 
the glaucoma patients had IOP less than or equal to their preoperative IOP, with the same 
number of glaucoma medications or less. Despite being a retrospective study it demonstrated 
a sustained reduction in IOP after cataract removal.
Slabaugh et al. [33] in a retrospective study of 157 patients with POAG found a decrease 
in IOP by a mean of 1.8 mmHg after phacoemulsification at 1 year follow-up but 38% had 
worsening of IOP control including 24% that needed additional medications or laser tra-
beculoplasty and 0.6% that required trabeculectomy. Among patients that did not have any 
change in medications, higher preoperative IOP, older age and deeper anterior chamber 
depth were associated with lower postoperative IOP.
The American Academy of Ophthalmology in a recent assessment investigated the long-
term effect of phacoemulsification on IOP in patients with POAG, PSX and PACG [34]. They 
found that higher IOP before phacoemulsification is the single most common significant fac-
tor associated with a greater drop in IOP after phacoemulsification and concluded that for 
patients with POAG controlled with 1 or 2 medications, phacoemulsification alone results in 
a decrease in IOP (−13%) and medication requirement (−12%) although 26% of patients expe-
rience worse IOP control after phacoemulsification and may require additional medications, 
laser treatment or both.
3.2. Cataract surgery and angle-closure glaucoma
The prevalence of primary angle-closure glaucoma is highest in Asia (1.09%) and there is an 
estimated of 23.4 million cases worldwide for 2020 [35].
Patients with chronic primary angle-closure glaucoma (PACG) have an altered trabecular 
meshwork architecture with fewer spaces and fused trabecular beams, these changes are the 
result of mild, recurrent subacute attacks of angle closure that lead to chronic angle-closure 
glaucoma [36].
In a large percent of patients, there are multiple mechanisms for angle-closure glaucoma as 
pupillary blocking and plateau iris, in those patents residual angle-closure post iridotomy 
would result in poor control of IOP, in those patients lens extraction may resolve residual 
angle closure [37]. Previous studies demonstrated that lens extraction has the ability to lower 
IOP, lens extraction would widen the angle even without structural alterations of plateau iris 
because the lens plays a central role in the pathogenesis of PACG, its increased thickness, rela-
tive anterior positioning and progression of its thickness result in narrowing of the anterior 
chamber.
Lens extraction reduces diurnal IOP fluctuations, IOP levels and the number of anti glaucoma 
medication in PACG with previous laser iridotomy, the change in IOP fluctuation values cor-
relates positively with the change in anterior chamber deep an preoperative IOP fluctuation 
[38]. Thus patients with narrowest angles might experience a greater benefit from cataract 
surgery alone depending on the proportion of the angle that has been permanently closed by 
peripheral anterior synechiae.
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In 1998, Gunning and Greve [39] retrospectively evaluated the long-term effects of extrac-
tion of incipient cataracts or clear lenses in patients with subacute or chronic angle-closure 
glaucoma, after a mean follow-up of 52.6 months glaucoma control was achieved in 68% of 
patients, they concluded that the choice of first a cataract procedure with the option of a 
future trabeculectomy may be a more attractive approach in patients with subacute or chronic 
angle-closure glaucoma than trabeculectomy followed by an optional cataract procedure.
In the EAGLE trial, they assessed the efficacy and of clear lens extraction versus laser periph-
eral iridotomy and topical medical treatment as first-line therapy in people with newly 
diagnosed primary angle closure and intraocular hypertension or primary angle-closure 
glaucoma. After a mean follow-up of 36 months, clear lens extraction showed greater efficacy 
and was more cost-effective than laser peripheral iridotomy, they concluded that clear lens 
extraction should be considered as an option for first-line treatment [40].
In a prospective study, Tham et al. [41] compared phacoemulsification alone versus combined 
phacotrabeculectomy in patients with PACG medically controlled, after 2 years follow-up 
combined surgery resulted in less topical glaucoma drugs but there were no differences in 
glaucomatous progression, also combined surgery was associated with more postoperative 
complications.
In another prospective study, Tham et al. [42] also compared phacoemulsification versus tra-
beculectomy in patients with PACG medically uncontrolled, alter 1 year follow-up, there was 
a significant and comparable reduction in IOP in both groups but trabeculectomy was more 
effective in reducing dependence on glaucoma drugs also with more postoperative complica-
tions. In the phacoemulsification group, only 27% did not require IOP-lowering medications 
or further surgery after 24 months.
The decision of a cataract surgery alone versus a combined surgery should be made taking 
account of the type of glaucoma, the severity of the disease and the IOP. Patients with a mild dam-
age and a controlled IOP with topical medications are good candidates for cataract surgery alone.
4. Surgical complications in combined surgery
Patients after glaucoma surgery have an increased risk of cataract formation or progression, 
approximately 50% of patients will require cataract surgery within the first years after trab-
eculectomy surgery [43].
Phacoemulsification in presence of a functioning filtration bleb increases the risk of bleb fail-
ure in 33%, there are changes in bleb morphology that results in elevations in intraocular pres-
sure (IOP), increased glaucoma medications or additional surgical treatment [44, 45].
The coexistence of cataract and glaucoma in the same patient can follow different strategies 
such as glaucoma surgery first, cataract surgery first or combined surgery, it depends of the 
type of glaucoma, the severity of the disease, target intraocular pressure, patients age and the 
preference of the surgeon.
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4.1. Phacotrabeculectomy
Although a staged approach of trabeculectomy followed by cataract surgery has demon-
strated successful refractive results, with the last improvements in phacoemulsification and 
trabeculectomy, phacotrabeculectomy stills a surgical option for some patients with cataract 
and glaucoma. The indications for phacotrabeculectomy are the simultaneous presence of a 
visually significant cataract and medically uncontrolled glaucoma, advanced glaucomatous 
optic nerve damage or visual field loss. A combined approach has the advantages of reduced 
overall cost, reduced anesthesia and surgery time and less recovery time.
In a retrospective study, Jin et al. [46] evaluated the outcomes after phacotrabeculectomy in 
consecutive patients. Over 60 patients included in the study, hyphema and hypotony devel-
oped in three eyes in the early postoperative period. Bleb hemorrhage occurred in two eyes 
and cleared within 2 weeks without incident, one eye had a bleb leak that resolved after con-
servative treatment. The most frequent late complication was posterior capsule opacification 
requiring capsulotomy in six eyes. Bleb revision was performed in two eyes for dysesthetic 
bleb 2–3 years after surgery. A second trabeculectomy and an injection of 5-fluorouracil were 
performed each in one eye, for poor filtration. In this study, the rate of complications was 
remarkable lower compared with other reports.
In another retrospective study in Singapore [47], the complications after phacotrabeculec-
tomy with Mitomycin C were evaluated, the mean follow-up was 47 months. Most of the 
postoperative complications occurred within the first month: hypotony in 25.6%, hyphema 
and shallow anterior chamber in 10% each one. About 11.3% of patients required surgical 
intervention: bleb needling with antimetabolite use in 4.4%, implant of glaucoma drainage 
device 1.3%, anterior chamber reformation 1.3% and lens repositioning 0.6%, the majority of 
complications were transient and self-limiting. They concluded that close and active monitor-
ing is critical in the early postoperative period to prevent complications and surgical failure.
There are reports of tilt and decentration of intraocular lens (IOLs) after phacoemulsification 
in patients with glaucoma; those are more common in eyes with pseudoexfoliation syndrome 
or closed-angle glaucoma.
In combined surgery, the changes in anterior chamber depth, axial length, changes in corneal 
curvature, iridectomy and fluctuations of IOP could affect the accuracy of the IOL power 
calculation and its position. Ong et al. [48] in a retrospective study investigated the refractive 
outcome of phacotrabeculectomy compared with a sequential approach, they found a greater 
myopic refractive prediction error and mean absolute error in the combined group. They 
advocate the surgeon aim for a slightly more hyperopic result for the combined approach to 
achieve results closer to emmetropia.
4.2. Combined phacoemulsification and glaucoma drainage implant
In the case of phacoemulsification combined with a glaucoma drainage device operative 
complications include anterior and/or posterior capsule tears, vitreous loss and IOL-capsular 
bag subluxation. Cataract extraction combined with implant insertion produce a moderate to 
severe reduction in IOP (hypotony) lasting for 1–14 days or more, after which the IOP return 
to safe levels. Other complications include hyphema, anterior chamber shallowing, choroidal 
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detachment associated with varying degrees of hypotony and IOP spikes [49]. Distended and 
symptomatic blebs could be seen in these patients and, most infrequently, diplopia.
Corneal decompensation after insertion of drainage devices and cataract extraction was 
likely to be due to pre-existing endothelial loss caused by previously uncontrolled IOP, but 
it is possible that endothelial injury may also be aggravated during phacoemulsification [39]. 
The hypertensive phase defined as elevated IOP in the presence of a functioning bleb and a 
patent tube and occurring up to 9 months after surgery was found to occur in similar rate 
than in the isolated drainage implant surgery (22–50%) [49–51]. Tube erosion and occlu-
sion show no difference between tube implant alone and when it is combined with cataract 
extraction [49–51].
4.3. Phacoemulsification and non-penetrating surgeries
There are several options to manage patients with both cataract and open-angle glaucoma 
and the rates of complications are different in non-penetrating surgeries compared with tra-
beculectomy. One of the advantages of phacoemulsification with non-penetrating surgeries 
versus phacotrabeculectomy is a lower incidence of postoperative inflammation and other 
immediate complications like hyphema and shallow anterior chamber.
In a retrospective study, Schoenberg et al. [52] compared the surgical outcomes between 
phaco canaloplasty and phacotrabeculectomy. There were no differences in overall failure 
rates between the two groups, in the phacotrabeculectomy group two patients had a decrease 
in vision but only one was related to the surgery. Five patients in each group required revision 
of the surgical site at the slit lamp for management of elevated IOP.
The most common complication in the phacocanaloplasty group was hyphema (27.7%) and 
resolved over a 2 week period in all patients. There were some serious complications during fol-
low-up, one patient in each group developed choroidal effusion, one patient had a suprachoroi-
dal hemorrhage and two developed hypotony maculopathy in the phacotrabeculectomy group. 
They concluded than phacocanaloplasty is an excellent option in patients with mild-to-moderate 
open-angle glaucoma but despite the higher risks of serious complications phacotrabeculectomy 
may be a good choice in patients with advanced glaucoma requiring greater IOP reduction.
A retrospective study [53] compared the outcomes of phacotrabeculectomy versus phaco-
emulsification-deep sclerectomy, there were no cases of bleb infections or endophthalmitis, 
hypotony occurred in only two patients who underwent laser goniopuncture after phaco-
emulsification-deep sclerectomy. The frequency of late bleb leaks was significantly higher in 
the phacotrabeculectomy group, there was a low incidence of immediate side effects in both 
groups but there was a high incidence of intraoperative perforations (15.7%) in the phaco-
emulsification-deep sclerectomy group.
A recent survey of the American Glaucoma Society [54] assessed the surgical practice patterns 
among their members in various clinical settings. In the case of a patient without prior inci-
sional surgery and with a visually significant cataract, 24% of surgeons performed phacotra-
beculectomy with mitomycin C, 22% phacoemulsification with minimally invasive glaucoma 
surgery and 9% phacoemulsification with a glaucoma drainage device versus 44% of sur-
geons that preferred phacoemulsification alone.
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The surgical approach for a patient with cataract and glaucoma has evolved over the years, 
improvements in previous surgical techniques and new available surgical options with less 
rates of complications has changed practice patterns among glaucoma surgeons.
5. Novel surgical approaches in cataract surgery
Cataract and glaucoma are ranked as the leading causes of blindness worldwide (51 and 8%, 
respectively) [55]. Both the cataract and glaucoma can coexist in elderly patient population. 
An estimate of 20% of cataract procedures performed annually in the USA has glaucoma or 
ocular hypertension. A combined cataract extraction with trabeculectomy has been the pre-
ferred surgical approach for managing cataract and glaucoma [56].
In developed countries, glaucoma is the second leading cause of irreversible blindness and 
this burden tends to increase as the population ages [57]. Similarly, for cataract, whose prev-
alence is also age-related the global prevalence of 15.5% increases to 45.9% in those over 
75 years and is expected to duplicate by 2020 [58].
Cataract surgery has been demonstrated to reduce IOP in glaucoma patients as well as 
in non-glaucomatous eyes, with variable magnitude depending on anterior chamber 
depth, angle configuration or the presence of concomitant pathology as pseudoexfolia-
tion syndrome [34]. Additionally, several series have demonstrated a greater IOP reduc-
tion postoperatively in elderly patients, females, eyes with an axial length ≤21 mm, and 
PXF patients [59]. Also, another beneficial effect of cataract removal can be observed in 
the capacity to increase the accuracy of functional and structural analyses currently used 
for diagnosing and evaluating glaucoma and its progression, since a visually significant 
cataract may act as an obstacle to these tests. Therefore, we can presume that combined 
treatment could be established, with cataract surgery being part of glaucoma treating stan-
dardized procedures.
5.1. Simultaneous or sequential cataract and glaucoma surgery
Currently, a variety of surgical procedures are available: first, phacoemulsification cataract 
extraction alone. Second, sequential glaucoma surgery and cataract extraction, and finally 
combined surgery. Phacoemulsification alone is suggested for controlled glaucoma patients 
with moderate and non-progressive visual field defect [59].
The severity of glaucoma must be taken into account for all cases of cataract surgery in glau-
coma patients’. In case of a refractory glaucoma, when more than three types of medication 
are required, with associated early stage cataract, it is advisable to postpone any phacoemul-
sification procedure until after glaucoma surgery [61]. Moreover, when phacoemulsification 
cataract extraction is performed after glaucoma surgery, it is advisable to verify bleb func-
tion, which could be reduced. For these cases, combined surgery is more beneficial due to 
an improvement on intraocular pressure decrease when compared to phacoemulsification 
alone [60, 61].
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5.2. Femtosecond-assisted cataract surgery in glaucoma
Femtosecond laser-assisted cataract surgery (FLACS), a new technology that was firstly intro-
duced in 2008 has shown promising treatment outcomes, has realized increasing popular-
ity [62]. Non-inferiority has been established relative to manual cataract surgery, and some 
reports have suggested superiority relative to manual methods [63]. Potential advantages 
include customized corneal incisions and capsulotomy position, precision in shape and size 
of capsulotomy, custom lens fragmentation patterns, endothelial cell loss reduction and better 
refractive stability and predictability [63].
To date, many studies have attempted to compare the outcome and complications of FLACS 
and conventional phacoemulsification cataract surgery. Some studies have shown better visual 
acuity recovery and lower endothelial cell loss after FLACS when compared with conventional 
phacoemulsification, in non-glaucoma patients [64, 65]. However, in glaucoma patients, the 
use of FLACS alone or in combination to filtering glaucoma surgery have been optimal, when 
taking into account postoperative visual recovery, corneal cell integrity and functionality [65].
With femtosecond laser technology and intraoperative image guidance, options for overcom-
ing major challenges in otherwise difficult cataract cases are now available [66]. Preoperative 
assessment of pupil dilation (4.0 mm or greater) and presence of iridocorneal or iridolen-
ticular adhesions is important in determining whether a patient with Peters anomaly is a 
candidate for femtosecond laser-assisted cataract extraction. Iridocorneal or iridolenticular 
adhesions that encroach on the central 4.0 mm of the visual axis may interrupt the laser capsu-
lotomy and may necessitate decentration of the capsulotomy or exclusion of the patient [62].
During femtosecond laser pretreatment in cataract surgery, suction is applied to stabilize the 
eye before laser anterior capsulotomy, main incision construction and lens fragmentation [67]. 
Recently reported data from femtosecond pretreatment in cataract surgery suggest that the 
above-mentioned vacuum application transiently increases intraocular pressure (IOP) [62, 67]. 
Moreover, large increases in IOP can cause vascular or rhegmatogenous events; however, Schultz 
et al., reported recently that during femtosecond pretreatment, the IOP increase in healthy eyes 
is small (mean peak increase 18.5 mmHg from baseline) and appears to be well tolerated [68]. 
Currently, it is not known whether glaucoma patients are more predisposed to the acute com-
plications or whether their response to vacuum applied during femtosecond laser pretreatment 
differs from that of patients without glaucoma [69]. Furthermore, a significant increase in IOP 
during laser pretreatment could result in nerve fiber damage and glaucoma progression.
5.3. Combined FLACS and glaucoma
5.3.1. Preoperative assessment
Laser-assisted cataract surgery patients should be evaluated for glaucoma. Therefore, a num-
ber of factors should be taken into account.
1. Glaucoma family history: it has been shown that people with familiar predisposition 
for glaucoma have increased risk of developing ocular hypertension and glaucoma. In 
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addition, these patients can develop glaucoma/OHT at a younger age. Therefore, glaucoma 
and visual field assessment is mandatory for patient’s undergoing cataract surgery [70].
2. Elevated IOP remains the most important, modifiable, risk factor for developing glaucoma. 
However, a single IOP measurement is not sufficient to assess the actual risk of glaucoma, 
especially when there are other coexisting risk factors, taking into account that transient 
increase on intraocular pressure is going to be induced by the docking procedure during 
laser pretreatment [71].
3. Other ophthalmic diseases: pigment dispersion as well as pseudoexfoliation syndrome 
have been associated to secondary open-angle glaucoma [72, 73]. Previous reports have 
demonstrated that the presence of pigment dispersion syndrome does not affect the re-
sults of refractive surgery; however, topical antiglaucoma medication before surgery can 
modify the healing process thus the corneal wound can last longer [74].
4. Hypermetropia: hypermetropes are more likely to have narrow anterior chamber angles and 
a case of acute angle closure after LASIK in a hypermetropic patient has been reported. Pre-
operative gonioscopy will help the surgeon to recognize patients with narrow angles [75].
5.4. Toric IOL in glaucoma patients
Cataract surgery has gradually changed from vision rehabilitation to refractive surgery, which 
aims to achieve the best visual quality with minimal surgical trauma. With improvements 
of surgical techniques, postoperative corneal astigmatism has become a key factor affecting 
postoperative visual quality. Surgical astigmatism is caused by many factors, of which surgi-
cal incision is the main factor. The application of phacoemulsification on a clear corneal inci-
sion can cause slight reverse astigmatism, suggesting that the healing process of clear corneal 
incision directly affects changes of corneal astigmatism. This astigmatism is caused by the 
structure of the corneal incision, and corneal biomechanical changes.
Femtosecond laser-assisted cataract surgery (FLACS), which includes lens fragmentation, 
clear corneal incisions, and limbal relaxing incisions, was first reported by Nagy et al. [64]. 
The clinical application of the femtosecond laser has led to new developments for cataract 
surgery. The femtosecond laser system can make ladder-like multi-plane incisions in which 
the inner surface is enclosed. That is, the ladder between the corneal surface and matrix is 
made first to improve the impermeability of the incision, maintain intraocular pressure (IOP) 
and anterior chamber stability and prevent leakage of aqueous humor, thus reducing the 
incidence of endophthalmitis. The femtosecond laser system was first used to complete the 
phacoemulsification steps including capsulorhexis, nucleus fragmentation and clear corneal 
incision. The patients were then subjected to phacoemulsification to complete the entire cut 
along the tunnel made in former steps using a puncture knife [65].
Pseudoexfoliation is related to both glaucoma and cataract. Particularly, these patients have a 
tendency to achieve a poor pupil dilation; in addition to weak zonules, iridodonesis, phaco-
donesis or lens subluxation [75, 76]. In addition, patients with PXF may have higher pressures 
in the postoperative phase [76].
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Toric IOLs might also not be successful in patients with an unstable capsular bag, or pseudo-
exfoliation and/or weak zonules, as the lens and bag may rotate or tilt once implanted, alter-
ing the patients’ vision. There is a potential error if a toric IOL is implanted at the same time 
a glaucoma procedure is done, since a glaucoma surgery might induce keratometric changes 
depending on sutures and their tension, and further changes may occur if those sutures are 
removed or lysed, negating any benefit from the toric implant [77].
5.5. Multifocal IOLs
Multifocal intraocular lenses platforms are indeed valid options for glaucoma patients; however 
some considerations should be noted regarding its selection. Several lenses affect the monitoring 
of visual fields, recent reports by Inoue et al., revealed that multifocal IOLs can reduce contrast 
sensitivity and may alter raw values, gray scale and mean deviation values. Further, increased 
glare may reduce the sensitivity [77]. In addition, multifocal IOL implants cause significant 
nonspecific reduction in mean deviation (MD) values in automated perimetry in healthy eyes 
with multifocal compared to monofocal intraocular lens (IOL) implants on Humphrey Visual 
Field 10-2 testing that does not improve with time or neuroadaptation [77, 78]. Multifocal IOL 
implants may be inadvisable in patients where central visual field reduction may not be toler-
ated, such as macular degeneration, retinal pigment epithelium changes and glaucoma.
Long-term medical therapy used for several glaucoma patients can induce some degree of 
pupil rigidity, and in these cases, it is advisable to avoid multifocal IOLs if pupil diameter is 
less than 3.5 mm. Nevertheless, diffractive multifocal IOLs, which are not pupil-size depen-
dent, can be considered for these patients. Irregular-shaped pupils, however, may increase 
the photopic symptoms and glare [77–79].
It is important to emphasize that multifocal platforms can be safely used in glaucoma sus-
pects and ocular hypertensive patients with no disk or visual field damage who have been 
stable. In addition, glaucoma patients with early or mild visual field damage that has been 
controlled and stable, as well as glaucoma patients with a level of glaucoma in the fellow eye 
that is similar, and not severe, advanced or progressive.
Large trials providing scientific evidence-based data on the impact of multifocal IOL’s in 
glaucoma patients, decisions regarding the implantation in a glaucoma patient should be 
individualized, taking into account patients’ motivation and the rate of progression of 
glaucoma.
6. Conclusions
Cataract surgery is one of the most performed surgeries in the developed world. In addition to 
its significant impact on visual acuity, it has a proven potential effect on IOP decrease, but does 
not reduce IOP peaks [55]. More than 20 million Americans over 40 have cataract symptoms 
and more than 3 million cataract surgeries are performed in this country each year [80]. On the 
other hand, cataracts and glaucoma are the main causes of blindness in the world (51 and 8%, 
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respectively). Glaucoma is the second cause of irreversible blindness, which increases with 
age [56]. Having both the same trend factor (age), they often coexist. Cataract has an overall 
prevalence of 15.5%, which increases to 45.9% in subjects older than 75 years and is estimated 
to be doubling by 2020 [58].
Does cataract and glaucoma coexistence represent a natural key to the management to both 
conditions? The answer to this question is under discussion, but it is important to note that 
30% of patients who underwent cataract surgeries in the United States in the Medicare pro-
gram had concomitant glaucoma [80, 81]. In addition, another study revealed that 9.1% of 
patients diagnosed with cataract coexist with the diagnosis of glaucoma [82].
Combined surgery seems to be the most understandable approach in the management of 
these two conditions. Cataract surgery in conjunction with conventional filtering procedures, 
such as trabeculectomy and valve implants, is indicated in patients with moderate to severe 
damage, although there is not real consensus [83, 84].
An important aspect of combined surgery is IOP peaks reduction. Traditional combined sur-
gery produces a significant reduction on IOP, but with a higher risk of complications.
It is at this point that MIGS represents a revolution in combined surgery for glaucoma patients, 
certainly the IOP reduction is moderate (20%), but the complications number is reduced, it is 
an additional option to mild glaucoma or topical drug intolerance.
With the advent of these devices, a new vision is established in the glaucoma management, 
in earlier stages, leaving behind the traditional concept of glaucoma surgery in moderate or 
severe damage, even more the combination of these procedures with phacoemulsification, 
defines a new paradigm not only in the IOP control, also in a more audacious and timely 
visual rehabilitation, inclusive some cases premium lens implant.
On the other hand, the implementation of these novel techniques, require a prominent 
knowledge of the angular anatomy and be a surgeon experienced in glaucoma surgery, 
moreover, provides the opportunity to experts in phacoemulsification, to perform mini-
mally invasive techniques and to do appropriate management in glaucomatous patients 
with mild damage. Cataract surgery with MIGS is an alternative in scrupulously selected 
patients (mild and moderate). There is insufficient evidence of the long-term intraocular 
pressure with these devices and techniques (MIGS) may become the most popular surgery 
in the glaucoma management and with a greater cost-benefit compared to topical treatment; 
however, there is not enough evidence on this, so it is advisable to consult it constantly and 
be cautious in the patient selection. Moreover, it is essential to recognize the inherent benefit 
of the combined procedure and the impact on the visual health and quality of life of our 
patients.
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